Artelo Biosciences
ARTL
4 hedge funds and large institutions have $78.4K invested in Artelo Biosciences in 2023 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.29% less ownership
Funds ownership: 1.66% → 1.37% (-0.29%)
29% less capital invested
Capital invested by funds: $111K → $78.4K (-$32.4K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.31K |
| 2 |
JP Morgan Chase
New York
|
+$657 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$13.5K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$5.52K |
| 3 |
CFD
Creative Financial Designs
Kokomo,
Indiana
|
-$167 |
ARTL Hedge Fund Activity: Q2 2023 in Review
4 of the 6,384 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q2 2023, worth a combined $78.4K — down 29% from $111K a quarter earlier.
Fund positioning in ARTL was balanced in Q2 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.31K. The largest seller was Two Sigma Advisers, cutting an estimated $13.5K.
- 4 institutional investors held Artelo Biosciences (ARTL) as of Q2 2023, unchanged from Q1 2023.
- Funds reported $78.4K of Artelo Biosciences stock for Q2 2023, down 29% quarter-over-quarter.
- 1 fund opened new Artelo Biosciences positions in Q2 2023 and 1 closed out, a net change of 0 holders.
- The largest Artelo Biosciences buyer in Q2 2023 was Tower Research Capital (TRC), an estimated $1.31K added.
- The largest Artelo Biosciences seller in Q2 2023 was Two Sigma Advisers, an estimated $13.5K sold.
Based on aggregated 13F filings for Q2 2023.